Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Separated animal oil or solidified form thereof derived from...
Reexamination Certificate
2006-05-23
2006-05-23
Flood, Michele (Department: 1655)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Separated animal oil or solidified form thereof derived from...
C424S078020
Reexamination Certificate
active
07048950
ABSTRACT:
An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatments. This lipid material is extracted from the Emu (Dromais Novae-Hollandiae), an indigenous bird of Australia and New Zealand. The present invention also discloses therapeutic compositions comprising Emu Oil in combination with an extracellular product ofBacillus coagulansorPseudomonas lindbergiistrain, comprising a supernatant or filtrate of said culture suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. Additionally, the aforementioned therapeutic composition may also include an anti-microbial, anti-mycotic, and/or anti-viral agent. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions comprising Emu Oil in combination with an extracellular product ofBacillus coagulansorPseudomonas lindbergiistrain suitable for topical application to the skin or mucosal membranes of a mammal. Similarly, the aforementioned method may also employ a therapeutic composition additionally containing an anti-microbial, anti-mycotic, and/or anti-viral agent.
REFERENCES:
patent: 4062943 (1977-12-01), Lindberg
patent: 4110477 (1978-08-01), Naruse et al.
patent: 5079164 (1992-01-01), Kirkovits et al.
patent: 5176911 (1993-01-01), Tosi et al.
patent: 5384134 (1995-01-01), Kross et al.
patent: 5431924 (1995-07-01), Ghosh et al.
patent: 5439678 (1995-08-01), Dobrogosz et al.
patent: 5472713 (1995-12-01), Fein
patent: 5698227 (1997-12-01), Rivlin
patent: 5744128 (1998-04-01), Holick
patent: 5849334 (1998-12-01), Rivlin
patent: 6083536 (2000-07-01), Macrides et al.
patent: 6103246 (2000-08-01), Tisdale
patent: 6399105 (2002-06-01), Collin
patent: 6531126 (2003-03-01), Farmer
patent: 6645506 (2003-11-01), Farmer
patent: 12252 (1976-09-01), None
patent: 16101 (1979-02-01), None
patent: WO 93/14187 (1993-07-01), None
patent: WO 94/11492 (1994-05-01), None
patent: WO 97/09992 (1997-03-01), None
patent: WO 98/33474 (1998-08-01), None
patent: WO 98/47374 (1998-12-01), None
Borovkov et al., Mikrobn. Metab. Ikj Ispol'z. Sel'sk. Khoz. (1973): 12-14. Editors: Voznyakovskaya et al. Inst. S-kh. Mikrobiol.: Leningrad, USSR.
Murray et al., Lett. Appl. Microbiol. (1986); 3(1): 5-7. Inhibition of fungal spore germination by gramicidin S and its potential use as a biocontrol against fungal plant pathogens.
Sussman, et al., 1986. Clinical manifestations and therapy ofLactobacillus endocarditis: report of a case and review of the literature. Rev. Infect. Dis. 8: 771-776.
Hata, et al., 1988. Meningitis caused by Bifidobacterium in an infant. Pediatr. Infect. Dis. 7: 669-671.
Reid, et al., 1990. Is there a role for lactobacilli in prevention of urogenital and intestinal infections? Clin. Microbiol. Rev. 3: 335-344.
Gibson, et al., 1995. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 106: 975-982.
Saavedra, 1994. Feeding ofBifidobacterium bifidumandStreptococcus thermophiliusto infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 344: 1046-109.
Mitchell, 1998. Rearming in the fight against bacteria. Lancet 352: 462-463.
Shannon, 1998. Multiple-antibiotic-resistant salmonella. Lancet 352: 490-491.
Thomason, et al, 1991. Bacterial vaginosis: current review with indications for asymptomatic therapy. Am. J. Obstet Gynecol. 165: 1210-1217.
Marsh, 1993. Antimicrobial strategies in the prevention of dental caries. Caries Res. 27:72-76.
Hill & Embil, 1986. Vaginitis: current microbiologic and clinical concepts. Can. Med. Assoc. J. 134: 321-331.
Fuller, R., 1989. Probiotics in man and animals. J. Appl. Bacteriol. 66: 365-378.
Nakamura, et al., 1988. Taxonomic study for Bacillus coagulans Hammer 1915. J. Systematic Bacterio. 38: 63-73.
Winberg, et al., 1993. Pathogenesis of urinary tract infection-experimental studies of vaginal resistance to colonization. Ped. Nephrol. 7: 509-514.
Goodman, et al., 1990. Drug absorption, bioavailability, and routes of administration. The Pharmacological Basis of Therapeutics, 8thEdition. Pergamon Press, Inc. pp. 5-10.
Zemtsov et al., “Moisturizing and cosmetic properties of emu oil: A pilot double blind study”, Australasian J. Dermatol. 37:159-162, 1996.
Whitehouse et al., “Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine”, Inflammopharmacology 6:1-8, 1998.
Hodges et al., “Potential biocontrol of sclerotina homeocarpa and bipolaris sorokiniana on the phylloplane ofPoa pratensiswith strains ofPseudomonassp.”, Plant Path., 43:500-506, 1994.
Borokov et al., Mikrobn. Metab. Ikj. Ispol'z. Sel'sk. Khoz. (1973). Editors: Vozayakovskaya et al. Inst. S-kh. Mikrobiol.: Leningrad, USSR.
Murray et al. , “Inhibition of fungal spore germination by gramicidin S and its potential use as a biocontrol against funal plant pathogens.” Lett. Appl. Microbiol. (196) 3:5-7.
Sussman, et al., 1986. Clinical manifestations and therapy ofLactobacillus endocarditis: report of a case and review of the literature.Rev Infect. Dis. 8: 771-776.
Hata, et al., 1988. Meningitis caused byBifidobacteriumin an infant.Pediatr. Infect. Dis. 7: 669-671.
Reid, et al, 1990. Is there a role for lactobacilli in prevention of urogenital and intestinal infections?Clin. Microbiol. Rev. 3: 335-344.
Gibson, et al., 1995. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin.Gastroenterology 106: 975-982.
Saavedra, 1994. Feeding ofBifidobacterium bifidumandStreptococcus thermophilusto infants in hospital for prevention of diarrhoea and shedding of rotavirus.Lancet 344: 1046-109.
Mitchell, 1998. Rearming in the fight against bacteria.Lancet 352: 462-463.
Shannon, 1998. Multiple-antibiotic-resistant salmonella.Lancet 352: 490-491.
Thomason, et al, 1991. Bacterial vaginosis: current review with indications for asymptomatic therapy.Am. J. Obstet Gynecol. 165: 1210-1217.
Marsh, 1993. Antimicrobial strategies in the prevention of dental caries.Caries Res. 27: 72-76.
Hill & Embil, 1986. Vaginitis: current microbiologic and clinical concepts.Can. Med. Assoc. J. 134: 321-331.
Fuller, R., 1989. Probiotics in man and animals.J. Appl. Bacteriol. 66: 365-378.
Nakamura, et al., 1988. Taxonomic study for Bacillus coagulans Hammer 1915.J. Systematic Bacterio. 38: 63-73.
Winberg, et al., 1993. Pathogenesis of urinary tract infection-experimental studies of vaginal resistance to colonization.Ped. Nephrol. 7: 509-514.
Zemtsov A. et al., “Moisturizing and cosmetic properties of emu oil: A pilot double blind study” Australian Journal of Dermatology, vol. 37, No. 3, 1996, pp. 159-162.
International Preliminary Examination Report.
Flood Michele
Ganeden Biotech, Inc.
Mintz Levin Cohn Ferris Glovsky and Popeo
LandOfFree
Use of Emu Oil and its various fractions as a carrier for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of Emu Oil and its various fractions as a carrier for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of Emu Oil and its various fractions as a carrier for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3623504